Wall Street Associates’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Wall Street Associates’s Portfolio KBIO Stock Details KBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-76,038	Closed	-$1.39M	–	366
2014 Q2	$1.39M	Sell	76,038 -375	-0.5%	-$6.42K	0.12%	194
2014 Q1	$1.66M	Sell	76,413 -1,737	-2%	-$50.3K	0.14%	184
2013 Q4	$2.76M	Hold	78,150	–	–	0.23%	134
2013 Q3	$2.83M	Buy	78,150 +26,525	+51%	+$1.21M	0.26%	125
2013 Q2	$2.34M	Buy	+51,625	New	+$2.34M	0.24%	130

Other funds holding KBIO

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIM

SSI Investment Management Los Angeles, California $1.72B AUM 7.09% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Wall Street Associates's KBIO Position: Q3 2014 in Review

Wall Street Associates sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q3 2014, closing a stake of 76,038 shares — an estimated $1.39M sold.

Wall Street Associates first reported a position in KBIO in Q2 2013 and held it in 5 quarters. The position peaked at $2.83M in Q3 2013. 35 funds tracked by Wall St. Rank hold KBIO as of Q3 2014.

Wall Street Associates reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q3 2014 after selling out during the quarter.
Wall Street Associates sold 76,038 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2014, an estimated $1.39M.
Wall Street Associates first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 5 quarters.
Wall Street Associates's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $2.83M in Q3 2013.
35 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2014.

Based on Wall Street Associates's 13F filing for Q3 2014, filed 13 Nov 2014.